ClinicalTrials.gg
Active, not recruitingNCT04467983Updated Oct 13, 2026

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

A Phase 4 interventional study of Denosumab Injection and Abaloparatide in Osteoporosis, Postmenopausal, sponsored by Hospital for Special Surgery, New York. Active, not recruiting at 1 site in United States. Open to female participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Hospital for Special Surgery, New York · Phase 4, Interventional, and Treatment

How we know

Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
45 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Osteoporosis, Postmenopausal with a site in United States — 4 open to participants now, 11 under way, 1 of them phase 3. Osteoporosis, Postmenopausal · United States.

Planned enrollment
64th of 95
70 · median 201
Started
2021
with 6 others
Phase 4
31 of 106
1 open now
Primary completion
2026-09
later than 2 of 10 live
Registered
91st of 106
by date

Among the 106 studies in Osteoporosis, Postmenopausal with a site in United States, this one is the 64th largest by planned enrollment of the 95 interventional ones that give a count, is one of 7 that started in 2021, is one of 31 in phase 4, reaches primary completion later than 2 of the 10 other live ones, and was the 91st registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

4 of the 106 studies in Osteoporosis, Postmenopausal with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 45 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Osteoporosis, Postmenopausal with a site in United States, or all of them as a file.
02

Study summary

This randomized open label clinical trial will evaluate the effect of continued denosumab alone over 18 months versus denosumab with added abaloparatide for 18 months. 70 postmenopausal women will be enrolled over a period of 18 months. The co-primary outcomes will be group differences in bone mineral density (BMD) of the total hip and lumbar spine at 18 months. Secondary outcomes will include group differences in bone mineral density (BMD) at the femoral neck, trochanter and wrist sites at 6, 12 and 18 months, spine and total hip bone mineral density (BMD) at 6 and 12 months and trabecular bone score (TBS) at 18 months. Secondary outcomes will also include within group changes from baseline for each of these variables. Bone turnover markers will also be measured to demonstrate that PINP levels will increase with administration of abaloparatide even in the setting of ongoing denosumab, while CTX levels will remain low.

Read the detailed description

Some women on denosumab treatment for osteoporosis remain at high risk for fracture. These include women who sustain incident fractures on denosumab and those who have declining bone mineral density (BMD) or persistently low bone mineral density (BMD), despite treatment. There are few options available for these patients. Denosumab withdrawal is associated with dramatic increased bone remodeling, rapid prominent bone loss, and multiple vertebral fractures (Cummings JBMR 2017). Switching from denosumab to teriparatide is associated with substantial BMD loss in the hip and femoral neck. After 2 years of denosumab treatment, when women are switched to teriparatide, total hip BMD remains below the baseline (at end of denosumab treatment) over the entire 2 years of teriparatide treatment (Leder Lancet 2015).

Abaloparatide might be a better option than teriparatide in patients switching from denosumab, because it is less pro-resorptive than teriparatide, however, hip BMD will still likely decline. Alternatively, adding abaloparatide to ongoing denosumab might be an excellent treatment option for these women. One of the investigators has previously shown that adding teriparatide to ongoing alendronate results in improved BMD and bone strength, compared to switching to teriparatide (Cosman JCEM 2009 and Cosman JBMR 2013). Others have shown that co-administration of teriparatide and denosumab to treatment naïve women increases BMD more than either agent alone (Tsai Lancet 2013, Leder et al JCEM 2014). Based on both of these observations, the investigators believe that adding abaloparatide to continued denosumab treatment will allow bone formation to increase, without increasing bone resorption (modeling-based bone formation) and will produce substantial BMD increments in both spine and hip.

Hypothesis: In women who still appear to be at high risk for fracture while receiving ongoing denosumab therapy, adding abaloparatide will increase BMD of the lumbar spine and total hip significantly more than continuing denosumab alone.

03

Conditions studied

  • Osteoporosis, Postmenopausal

Keywords

  • denosumab
  • abaloparatide
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • woman >age 45 of any racial origin
  • Participants will have received at least 4 prior denosumab treatments and be within 7 months from their last denosumab injection
  • Participants are willing to participate for the duration of the study and have no physical or psychological illness that would prohibit them from participating.
  • Diagnosis of osteoporosis based on bone mineral density and/or fracture criteria. Osteoporosis will be defined by bone mineral density T-Score \< -2.5 at lumbar spine (at least 2 evaluable vertebrae between L1 and L4), total hip or femoral neck. Osteoporosis will also be defined clinically in women with osteoporotic fractures within the preceding 5 years, including clinical vertebral or nonvertebral fractures or vertebral fracture confirmed by radiograph or lateral DXA VFA image, along with a DXA BMD T-Score \< -1.5 at one or more skeletal sites.

Exclusion criteria

Exclusion Criteria:

  • Use of drugs other than denosumab (within the preceding 3 months) known to affect skeletal or calcium homeostasis.
  • Fewer than 2 evaluable lumbar vertebrae
  • A history of a symptomatic renal stone within the past 2 years or history of multiple symptomatic renal stones within the preceding 10 years
  • Skeletal Disorders other than osteoporosis, including hypercalcemia, hyperparathyroidism, or Paget's Disease
  • History of external or internal radiation therapy
  • Estimated below 30 ml/min
  • Any to receipt of Abaloparatide or Denosumab
  • History of any cancer in past 5 years (except basal/squamous skin cancer)
  • Unexplained elevation of Serum Alkaline Phosphatase
  • History of atypical femoral fracture
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Denosumab alone

    3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.

    Drug: Denosumab Injection

  • Active comparator
    Combination therapy

    3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.

    Drug: Denosumab Injection · Drug: Abaloparatide

Interventions

  • DrugDenosumabStudies of DenosumabDenosumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Denosumab alone: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.

    Also known as: Prolia

  • Combination therapy: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.

    Also known as: Tymlos

06

What researchers measure

Primary outcomes

  1. Bone mineral density changes at total hip and lumbar spine

    Group differences in BMD increment at total hip and lumbar spine at 18 months.

    Time frame: 18 months

Secondary outcomes

  1. Bone mineral density changes in increments

    Group Differences in BMD increments: of lumbar spine and total hip at 6 and 12 months. of femoral neck, and 1/3 radius at 6, 12 and 18 months. Group Differences in BMD increments: of lumbar spine and total hip at 6 and 12 months. of femoral neck, and 1/3 radius at 6, 12 and 18 months. Group Differences in BMD increments: of lumbar spine and total hip at 6 and 12 months. of femoral neck, and 1/3 radius at 6, 12 and 18 months. Group differences in BMD increments of lumbar spine and total hip (at 6 and 12 months) and of femoral neck and 1/3 distal radius (at 6, 12, and 18 months)

    Time frame: 6, 12, 18 months

  2. Trabecular Bone Score changes

    Group differences in Trabecular Bone Score at 18 months

    Time frame: 18 months

  3. Within Group Increments in bone mineral density (vs baseline)

    Within Group Increments in bone mineral density vs baseline of lumbar spine (at 6, 12, and 18 months) and of total hip, femoral neck, and distal 1/3 radius (at 6, 12, and 18 months)

    Time frame: 6, 12, 18 months

  4. Differences in biochemical bone turnover markers

    Within and between group differences in biochemical bone turnover markers (P1NP and CTX) at 3, 6, 12, and 18 months

    Time frame: 3, 6, 12, 18 months

07

Study locations

1 site
08

References and documents

Publications

  • Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015 Sep 19;386(9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5. Epub 2015 Jul 2. PubMed 26144908 ↗
  • Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab. 2009 Oct;94(10):3772-80. doi: 10.1210/jc.2008-2719. Epub 2009 Jul 7. PubMed 19584192 ↗
  • Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res. 2013 Jun;28(6):1328-36. doi: 10.1002/jbmr.1853. PubMed 23281041 ↗
  • Leder BZ, O'Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2015 Feb;100(2):697-706. doi: 10.1210/jc.2014-3718. Epub 2014 Nov 13. PubMed 25393645 ↗
  • Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, Lee H, Neer RM. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014 May;99(5):1694-700. doi: 10.1210/jc.2013-4440. Epub 2014 Feb 11. PubMed 24517156 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Sep 2026, 67 months.

Of 27 phase 4 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 67 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2020
First posted
Jul 13, 2020
StartActual
Feb 1, 2021
Primary completionActual
Sep 18, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 1, 2026→Sep 18, 2026 (actual)
Oct 13, 2026
Study completion
Dec 1, 2026→Dec 31, 2026
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Sep 1, 2026→Sep 18, 2026 (now actual)
    Study completion Dec 1, 2026→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04467983
Collaborators
Radius Health, Inc., Crozer-Keystone Health System
Responsible party
Joseph Lane, MD (Principal Investigator, Hospital for Special Surgery, New York) — Principal investigator
First posted
Jul 13, 2020
Start date
Feb 1, 2021
Primary completion
Sep 18, 2026
Completion
Dec 31, 2026 (estimated)
Last update
Oct 13, 2026

Study contacts

Jeri W Nieves, PhD
study director · Hospital for Special Surgery, New York

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abaloparatide

Start the discussion